Markets
local & international
Asia Pacific
Currencies
Commodities
UK
North America
News
latest news
Latest News
Most Viewed
Business
Currencies
Economy
Markets
Property
Technology
Portfolio
analysis & tools
Portfolios
Alerts
Filters
Reports
Watchlists
Help
Products
products & services
Charting
Data Agent
Data Subscriptions
Historical Data
Investment Game
Pricing
Real Edge
Download
Login
Register
Tuesday, 21 May 2013
ALIMERA SCIENCES INC
NASDAQ
ALIM
Summary
|
Chart
|
News
|
History
|
More info..
NASDAQ : ALIM
4.380
20 May 13 00:00
Change:
0.20
Open:
4.230
High:
4.420
Ask:
0.000
Volume:
71,100
Change(%):
4.78
Prev:
4.180
Low:
3.920
Bid:
0.000
Open Int:
0
Latest News
More news...
Financings of the Fortnight Waits For Public Investors To Hop On Bluebird
03:51 | 18/5/13
The IN VIVO Blog (blog)
You don't have to be the sharpest tool in the shed to notice how life-science IPOs have re-inserted themselves into the daily chatter this year, and there's one upcoming issue that makes for fascinating conversation: bluebird bio, a big-idea company ...
more»
Drug Manufacturer Top losers, Alimera Sciences Inc (NASDAQ:ALIM), Rockwell ...
22:43 | 16/5/13
Crazy Joys
Other drugs shares also showed some relative strength, up on the day by about 1 percent as a group, led by Alimera Sciences Inc (NASDAQ:ALIM). The company announced on May 1st that its recent resubmission of the New Drug Application for ILUVIEN has ...
more»
Nasdaq stocks posting largest volume increases
10:15 | 15/5/13
MSN Money
Alimera Sciences Inc. : Approximately 921,000 shares changed hands, a 2,254.8 percent increase over its 65-day average volume.
more»
Another Solid Day For Wall Street
10:04 | 15/5/13
AdviceTrade
Low-priced Alimera Sciences, Inc. (ALIM) advanced 88 cents to 4.84, or 22%, on nearly a million shares. Revolution Lighting Technologies, Inc. (RVLT), a swing trade and favorite of ours, climbed 48 cents to 3.58, or 16%, on 1.4 million shares.
more»
pSivida Corp. Reports Third Quarter Fiscal Year 2013 Results
10:53 | 14/5/13
FierceBiotech
“We are very pleased that the FDA has accepted Alimera Sciences' recently resubmitted New Drug Application for ILUVIEN® for chronic Diabetic Macular Edema (DME) and has set a PDUFA target date of October 17, 2013.
more»
Comments
There are currently no comments on this topic.
Be the first person to Add a Comment...
ADD USER TO MY FAVOURITE
Customize your favourite:
Send me an alert when this user publishes new articles.
Add a Comment
You must be a registered user to post a comment:
REGISTER NOW
If you are already registered, please
LOGIN NOW
Add to Watchlist
Add to Portfolio
Add Email Alert
Global Indices
Code
Last
Change
NZ50
4,586
13
0.28%
COMP
3,496
3
0.07%
DJI
15,335
19
0.12%
SP500
1,666
1
0.07%
DAX
7,789
91
1.15%
FTSE
6,756
33
0.48%
NI225
12,494
22
0.18%
TWI
76.98
0.15
0.19%
Most Viewed Stories
More news...
04:05
New Zealand Dollar Rebounds Vs Greenback; Eyes On Bernanke
17:30
NZ dollar pares loss as investors kept wary
17:28
New Zealand Dollar Rebounds Vs Greenback; Eyes On Bernanke
18:08
MARKET CLOSE: NZ shares rise, led by F&P Healthcare
08:01
Australian dollar could dive below 90 US cents in coming weeks
Currencies
Code
Last
Change
EURUSD
1.289
0.000
0.01%
NZDUSD
0.8179
0.0005
0.06%
AUDUSD
0.9807
0.0005
0.05%
NZDAUD
0.8340
0.0005
0.06%
Newsletters
Email Address:
Weekly Newsletter
Daily NZX Report
Daily Market Report
Daily Forex Report
Daily Global Report